Related Experiment Videos
Robustaflavone, a potential non-nucleoside anti-hepatitis B agent
D E Zembower1, Y M Lin, M T Flavin
1MediChem Research, Inc., Lemont, IL 60439, USA.
Antiviral Research
|November 7, 1998
Summary
Robustaflavone effectively inhibits hepatitis B virus (HBV) replication. It shows synergistic effects when combined with antiviral drugs like penciclovir and lamivudine, enhancing anti-HBV activity.
Area of Science:
- Natural Products Chemistry
- Virology
- Pharmacology
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern.
- Developing novel antiviral agents is crucial for managing HBV.
- Naturally occurring compounds offer potential therapeutic avenues.
Purpose of the Study:
- To evaluate the anti-HBV activity of robustaflavone, a biflavonoid from Rhus succedanea.
- To assess the cytotoxicity and synergistic potential of robustaflavone in combination with established antivirals.
Main Methods:
- In vitro assessment of HBV replication inhibition in 2.2.15 cells.
- Determination of effective concentration (EC50) and selectivity index (SI).
- Combination studies with penciclovir and lamivudine using the Combostat program.
Main Results:
- Robustaflavone demonstrated potent HBV replication inhibition (EC50 = 0.25 microM, SI = 153).
- Robustaflavone hexaacetate showed activity with no cytotoxicity up to 1000 microM.
- Synergistic anti-HBV effects were observed with penciclovir and lamivudine, significantly improving EC50 and SI values.
Conclusions:
- Robustaflavone is a promising natural compound for HBV therapy.
- Combination therapy with robustaflavone and antivirals like penciclovir or lamivudine offers enhanced efficacy.
- Further research into robustaflavone's mechanism and clinical application is warranted.